Harrow (HROW) said Wednesday it has relaunched Verkazia 0.1% for the treatment of vernal keratoconjunctivitis, an allergic eye disease that mainly affects children.

Verkazia, or cyclosporine ophthalmic emulsion, is now backed by a commercial strategy that covers physician education, patient access, and affordability initiatives to ensure its supply and accessibility, Harrow said.

Shares of Harrow were down 1.3% in premarket activity Wednesday.